Arcus Biosciences (RCUS) fell ~14% in the premarket on Friday after the company announced the discontinuation of a Phase 3 ...

The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...

Arcus Biosciences and Gilead Sciences are discontinuing a Phase 3 trial of an experimental cancer treatment after an interim review showed the therapy was unlikely to help patients live longer.

Arcus Biosciences said on Friday it would stop a late-stage study testing its experimental cancer drug combination in ...

Arcus will now refocus its efforts outside of TIGIT, specifically on its asset casdatifan, an HIF-2a inhibitor once backed by Gilead, as well as its earlier stage small-molecule inflammatory and ...

A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another ...

Gilead and Arcellx reported promising data for their CAR-T therapy anito-cel at the annual American Society of Hematology ...

– Gilead Also Recently Submitted Applications for Lenacapavir for PrEP to the European Medicines Agency That Will Be Reviewed Under Accelerated Assessment Review Timeline – FOSTER CITY, ...

Drugmaker Gilead has announced that its new, twice-a-year shot of lenacapavir reduced HIV infections by 96% in a Phase 3 clinical trial. The company will next seek approval from the U.S. Food and Drug ...

Gilead gave the money to doctors who spoke at HIV Speaker Program events in the form of honoraria payments, meals and travel expenses, according to the U.S. Attorney's Office in Manhattan, which said ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for ...